# CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma

> **NCT01806337** · PHASE2 · COMPLETED · sponsor: **University of Göttingen** · enrollment: 41 (actual)

## Conditions studied

- Peripheral T-Cell Lymphoma

## Interventions

- **DRUG:** Alemtuzumab

## Key facts

- **NCT ID:** NCT01806337
- **Lead sponsor:** University of Göttingen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** 2006-07
- **Final completion:** 2011-02
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2013-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01806337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01806337, "CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01806337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*